Latest Report on ImmunoCellular Therapeutics Post Earnings

August 31, 2016   |   9:15 am

Contributor: Robert Hunter, Research Driven Investing

ImmunoCellular Therapeutics Ltd. (NYSE MKT: IMUC) shares gained 2.11 percent to close at $0.126 a share Tuesday. The stock traded between $0.12 and $0.13 on volume of 4.40 million shares traded. The stock appears to be facing some resistance at $0.13 and $0.14 with some support at $0.12. Shares of ImmunoCellular Therapeutics have fallen approximately 64.5 percent year-to-date and are down roughly 33.0 percent in the past month. Register with us now for your free membership and gain access to our latest Biotech reports at:

ImmunoCellular Therapeutics Profile

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated.

ImmunoCellular’s pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on cancer stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Get Your Up-To-Date ImmunoCellular Research Report at

Recent Earnings

The company reported a net loss of $5.3 million, or $0.06 per basic and diluted share, for the second quarter of 2016, compared to a net loss of $3.2 million, or $0.03 per basic and diluted share, in the second quarter of 2015. As of June 30, 2016, ImmunoCellular had $11.9 million in cash. During the second quarter 2016, ImmunoCellular incurred $4.4 million of research and development expenses.

Executive Comments

“We are pleased with the progress we made in the first half of this year, and believe that 2016 will be a year of accomplishment for our company. The first patient in the ICT-107 phase 3 trial was treated in June – a major achievement for our company. Today, more than 140 patients have been screened and clinical site activation is accelerating. We currently have activated 60 clinical sites in the US, two in Canada, and one in the UK, with more expected to come in the third quarter. With ICT-107, ImmunoCellular is one of a small number of companies in the cancer immunotherapy arena that we believe to be in the final stage of clinical development. In light of these achievements, our confidence remains high for the value and quality of our phase 3 program, and the therapeutic and commercial potential of ICT-107,” stated Andrew Gengos, ImmunoCellular Chief Executive Officer.

Get Your Up-To-Date ImmunoCellular Research Report at

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Hemal K. Gandhi, a CFA® charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.